GW Pharmaceuticals, along with its U.S. subsidiary Greenwich Biosciences, announced that EPIDIOLEX (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.    EPIDIOLEX, which was approved by the FDA on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high ...